AmpliPhi Biosciences
Armata Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant bacterial infections. The company aims to set the highest standards for safety and efficacy in phage-based treatments, addressing the global challenge of antibiotic resistance through innovative science and high-quality manufacturing. The company is actively involved in scientific research, regulatory discussions, and biofilm removal strategies related to bacteriophage therapy.
Industries
Nr. of Employees
small (1-50)
AmpliPhi Biosciences
Richmond, Virginia, United States, North America
Products
Investigational bacteriophage therapeutic programs (clinical-stage pipeline)
Clinical-stage investigational programs focused on pathogen-targeted bacteriophage therapies for antibiotic-resistant or difficult-to-treat bacterial infections.
Investigational bacteriophage therapeutic programs (clinical-stage pipeline)
Clinical-stage investigational programs focused on pathogen-targeted bacteriophage therapies for antibiotic-resistant or difficult-to-treat bacterial infections.
Services
Partnership and business development for phage technology
Engagement and partnering discussions to explore licensing, collaboration, or development opportunities related to bacteriophage therapeutics.
Partnership and business development for phage technology
Engagement and partnering discussions to explore licensing, collaboration, or development opportunities related to bacteriophage therapeutics.
Expertise Areas
- Bacteriophage therapeutics development
- Phage engineering and synthetic biology
- Formulation development and CMC for biologics
- cGMP clinical manufacturing and clinical trial material release
Key Technologies
- Bacteriophage isolation and characterization
- Synthetic biology for phage engineering
- Formulation development for biologics
- cGMP clinical-scale manufacturing